drugset
drugset / Trial / NCT06088264

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

NCT06088264 ↗

Phase 1 Completed 8 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.

Timeline

Start
2023-10-31
Primary completion
2023-12-22
Completion
2023-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject LOMECITINIB Small molecule — —

Indications

No indication recorded.